P27Kip1, regulated by glycogen synthase kinase-3β, results in HMBA-induced differentiation of human gastric cancer cells by Wei, Min et al.
RESEARCH ARTICLE Open Access
P27
Kip1, regulated by glycogen synthase kinase-
3b, results in HMBA-induced differentiation of
human gastric cancer cells
Min Wei
1, Zhiwei Wang
1, Hongliang Yao
2, Zhongyin Yang
1, Qing Zhang
1, Bingya Liu
1*, Yingyan Yu
1, Liping Su
1,
Zhenggang Zhu
1 and Qinlong Gu
1*
Abstract
Background: Gastric cancer is the second most common cause of global cancer-related mortality. Although
dedifferentiation predicts poor prognosis in gastric cancer, the molecular mechanism underlying dedifferentiation,
which could provide fundamental insights into tumor development and progression, has yet to be elucidated.
Furthermore, the molecular mechanism underlying the effects of hexamethylene bisacetamide (HMBA), a recently
discovered differentiation inducer, requires investigation and there are no reported studies concerning the effect of
HMBA on gastric cancer.
Methods: Based on the results of FACS analysis, the levels of proteins involved in the cell cycle or apoptosis were
determined using western blotting after single treatments and sequential combinations of HMBA and LiCl. GSK-3b
and proton pump were investigated by western blotting after up-regulating Akt expression by Ad-Akt infection. To
investigate the effects of HMBA on protein localization and the activities of GSK-3b, CDK2 and CDK4, kinase assays,
immunoprecipitation and western blotting were performed. In addition, northern blotting and RNase protection
assays were carried out to determine the functional concentration of HMBA.
Results: HMBA increased p27Kip1 expression and induced cell cycle arrest associated with gastric epithelial cell
differentiation. In addition, treating gastric-derived cells with HMBA induced G0/G1 arrest and up-regulation of the
proton pump, a marker of gastric cancer differentiation. Moreover, treatment with HMBA increased the expression
and activity of GSK-3b in the nucleus but not the cytosol. HMBA decreased CDK2 activity and induced p27Kip1
expression, which could be rescued by inhibition of GSK-3b. Furthermore, HMBA increased p27Kip1 binding to
CDK2, and this was abolished by GSK-3b inhibition.
Conclusions: The results presented herein suggest that GSK-3b functions by regulating p27Kip1 assembly with CDK2,
thereby playing a critical role in G0/G1 arrest associated with HMBA-induced gastric epithelial cell differentiation.
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Background
Gastric cancer is one of the most common cancers in the
world and often develops resistance to chemotherapy and
radiation treatments. Therefore, combination therapy has
been proposed to tackle the disease better and to reduce
the probability of developing resistance [1]. Hexamethylene
bisacetamide (HMBA), a hybrid polar compound (HPC)
originally developed as a differentiation-inducing agent
[2-6], causes gastric cell re-differentiation [7-9].
In the stomach, stem cells in the proliferative cell zone
of the isthmus region of the gastric glands differentiate
a n dg i v er i s et ov a r i o u sc e l lt y p e s[ 1 0 , 1 1 ] .O n c et h ef i r s t
tumorigenic event takes place, further tumor progression
depends on the nature of the initiating event and the
developmental stage of the cell that sustained it and addi-
tional mutations that could occur. Constant proliferation
is a vital feature of stem cells, and in gastrointestinal
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altered stem cells, increasing the probability of additional
mutations and tumor progression [12]. Therefore, target-
ing gastric cancer stem cells is likely to be the most effec-
tive way of treating gastric cancer. Approximately 50% of
the western population develops metaplasia, a key step in
cancer development [13], drawing attention to pathways
that control proliferation and thereby cell differentiation.
Among these, the TGF-b, Myb, Wnt and Hedgehog path-
ways are of particular relevance, featuring prominently in
cell-fate specification and pattern formation during
embryogenesis and adult tissue renewal. The elucidation
of complex tumor suppressor and accelerator signaling
pathways, which effect differentiation modulation of tran-
sitional/progenitor cells, will be pivotal for optimization
of therapeutics to treat gastric cancer.
In order for immature gastric cells to differentiate,
they require to stay in the G1 phase of the cell cycle for
a certain time period. The mammalian cell cycle is regu-
lated by sequential activation and inactivation of a
highly conserved family of cyclin dependent kinases
(CDKs); progression through early to mid-G1 is depen-
dent on CDK4 and possibly CDK6, while progression
through late G1 and the S phase requires activation of
CDK2. The activities of CDKs can be inhibited by the
binding of CDK inhibitory proteins including the Cip/
Kip family (p21
Waf1,p 2 7
Kip1 and p57
Kip2)a n dI N K 4
family (p15Ink4b, p16Ink4a, p18Ink4c and p19Ink4d).
P27
Kip1 is regulated post-transcriptionally by proteolytic
degradation. CDK2 binds to p27
Kip1 and phosphorylates
it on threonine 187 [14], and HMBA-induced gastric
cell differentiation is associated with the up-regulation
of p27
Kip1 [15,16] and G0/G1 arrest. However, there are
few detailed studies concerning the molecular mechan-
ism of HMBA and there have been no reported studies
investigating the effect of HMBA on gastric cancer.
As a downstream target of the phosphatidylinositol-3
kinase/Akt (PI3-kinase/Akt) pathway, GSK-3b regulates
cell proliferation and differentiation [17-20]. Accumulat-
ing evidence indicates that hypoactive GSK3b signaling,
which functions in G1 to receive input from several sig-
naling and developmental pathways, occurs in associa-
tion with diverse human cancers [21,22]. GSK-3b has
been implicated in multiple biological processes because
it phosphorylates a broad range of substrates including
several differentiation checkpoints including c-Myc,
snail and PI3K [23]. Previously, inhibition of the PI3-
kinase pathway was shown to enhance HMBA-mediated
gastric cell differentiation [8]. In this study, the role of
GSK-3b during gastric cell differentiation was investi-
gated using the human gastric cancer cell line SGC7901,
which displays a multipotent phenotype and represents
a well-characterized model of gastric differentiation. The
results suggest a contributory role for GSK-3b in the
p27
Kip1 pathway during gastric cell differentiation
induced by HMBA.
Methods
Cell culture
The gastric cancer cell line SGC7901 was obtained from
the cell bank in the Chinese Academy of Sciences and
cultured as previously described [24]. SGC7901 cells
were infected with an adenovirus encoding the activated
form of Akt (Ad-Akt) or the adenoviral control vector
encoding b-galactosidase (b- g a l )a tam u l t i p l i c i t yo f
infection (MOI) of 10 pfu/cell. After infection with vec-
tors for one hour, followed by replacement of medium
and incubation for a further 24 h, cells were treated in
the presence or absence of HMBA, and protein and
RNA were extracted for western and Northern blotting,
respectively.
Materials
HMBA, TSA, SB-415286 and LiCl were purchased from
Sigma Chemical Company, USA. Adenovirus vectors
encoding b-gal and the myristoylated active form of Akt
(Ad-Akt) were purchased from Cell BioLabs, USA. The
vector encoding the catalytically active mutant of
GSK3b (HA-GSK-3bCA) was purchased from Addgene.
Non-targeting control siRNA and the SMARTpool for
targeting GSK-3b were purchased from Dharmacon,
USA. All probes were labeled with a Biotin Random
Prime DNA Labeling Kit (Pierce).
Antibodies
Rabbit anti-Akt, anti-phospho-Akt (Ser473) and anti-
phospho-GSK-3b (Ser9) were purchased from Cell
Signaling, USA. Mouse anti-GSK-3b,m o u s ea n t i -
p27
Kip1, mouse anti-Top IIb and mouse anti-p21
Waf1
were purchased from BD Biosciences, USA. Mouse anti-
phospho-GSK-3 (Tyr278/Tyr216) was obtained from
Upstate, USA. Rabbit anti-cleaved PARP antibody was
purchased from Abcam, USA. Anti-proton pump was
bought from MBL International (USA). Polyclonal anti-
CDK2, anti-CDK4, anti-a-tubulin and anti-caspase-3
were obtained from Santa Cruz Biotechnology (USA).
Sub-cellular protein extraction and western blotting
Nuclear and cytosolic fractions were extracted using a
NE-PER Nuclear and Cytoplasmic Extraction Reagents
kit (Pierce, USA). Cytosolic protein (80 mg) or nuclear
protein (20 mg) was resolved on a 10% polyacrylamide
gel and transferred to PVDF membranes as previously
described [25]. Filters were incubated for one hour at
room temperature in blotting solution. Membranes
were incubated overnight at 4°C with primary
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oxidase-conjugated secondary antibody for one hour,
and visualized using an ECL detection system.
Northern blotting and RNase protection assays (RPA)
Total RNA was prepared using TRIzol reagent (Invitro-
gen). Samples were run on 1.2% agarose/formaldehyde
gels and transferred to supported nitrocellulose. Mem-
branes were hybridized with a biotin labeled gastric pro-
ton pump cDNA probe. After hybridization with the
GAPDH probe, a loading control, membranes were
washed and signals were detected using an ECL detec-
tion system. RNase protection experiments were per-
formed using the RPA-III kit from Ambion and the
RiboQuant MultiProbe RNase Protection Assay System
was utilized to detect multiple specific mRNAs.
32P-
labeled antisense RNA probes were prepared using the
Human Apoptosis hCC-2 and hCYC-1 Template Sets
and hybridizations were performed according to the
manufacturer’s protocol.
Cell cycle analysis
Gastric cancer cells were harvested using trypsin. Cells
were collected, washed twice with ice-cold PBS and
fixed in ice-cold 70% ethanol. After being washed twice
with ice-cold PBS, resuspended in PBS containing
100 U/ml RNase A and incubated at 37°C for 30 min,
cells were stained with PI (20 mg/ml) and analyzed
using FACScan (Becton Dickinson, San Jose, CA, USA),
as previously described [25].
In vitro kinase assays
The activities of CDK2, CDK4 and GSK-3b were mea-
sured as previously described [26,27]. Briefly, CDK2,
CDK4 or GSK-3b was immunoprecipitated from cytoso-
lic (100 mg of protein) or nuclear (25 mg of protein)
extracts. Kinase activity was measured by incubating
immunoprecipitated CDK2, CDK4 or GSK-3b in 40 ml
of kinase buffer with 4 mg recombinant Snail protein
(to measure GSK-3b-associated kinase activity), 5 mg of
histone H1 (to measure CDK2-associated kinase activity)
or retinoblastoma protein (to measure CDK4-associated
kinase activity) at 30°C for 30 min. The samples were
processed as described in previous reports [28].
Results
Inhibition of GSK-3b attenuates HMBA-induced cell cycle
arrest and SGC7901 cell differentiation
SGC7901 cells accumulated at the G0/G1 cell cycle
checkpoint and differentiated into an enterocyte-like
phenotype after treatment with HMBA [29]. GSK-3b
contributes to the inhibition of cell cycle progression
in differentiating cells [20,30]. Therefore, whether
GSK-3b plays a role in HMBA-induced SGC7901 cell
cycle inhibition was investigated. As demonstrated in
Figure 1a, treatment with HMBA induced cells to
accumulate at the G0/G1 cell cycle checkpoint. Treat-
ment with lithium chloride (LiCl), which inhibits GSK-
3b in a Mg
2+ competitive manner [31], increased the
proportion of cells in the S phase. Treatment with a
combination of LiCl and HMBA reversed HMBA-
mediated G1 cell arrest. Similar results were obtained
after treatment with SB-415286, a potent inhibitor of
GSK-3b [32] (Additional file 1). These results suggest
that GSK-3b c o u l dp l a yar o l ei nH M B A - i n d u c e dG 1
arrest. To determine whether HMBA resulted in cell
death during the 24 h treatment period, protein was
extracted to assess whether there was increased PARP
cleavage and/or active caspase-3. As demonstrated in
Figure 1b, there was no increase in PARP cleavage and
active caspase-3 until 48 h after HMBA treatment. An
important early event in the terminal differentiation of
cells is their withdrawal from the cell cycle [6]. Since
GSK-3b is documented to play a role in cell cycle
arrest [33], it was postulated that inhibition of GSK-3b
could inhibit differentiation. Therefore the effects
of GSK-3b inhibitors on the induction of HMBA-
mediated gastric proton pump expression, a marker of
gastric differentiation, were examined. SGC7901 cells
were pre-treated with LiCl (Figure 1c and 1d) or SB-
415286 (Figure 1e and 1f) at various concentrations for
one hour, and then treated with HMBA for 24 h. LiCl
inhibited HMBA-induced gastric proton pump expres-
sion in a dose-dependent manner. Consistent with
these results, SB-415286 blocked gastric proton pump
protein and mRNA expression, which was induced by
HMBA. Taken together, these results indicate that
GSK-3b plays an important role in HMBA-mediated
gastric cell differentiation.
Akt regulates gastric differentiation induced by HMBA
GSK-3b is inactivated when it is phosphorylated down-
stream of Akt [34]. Therefore, it would be predicted
that activation of Akt by PI3-kinase would be associated
with inhibition of GSK-3b and, subsequently, inhibition
of gastric cell differentiation. To test this hypothesis,
SGC7901 cells were infected with Ad-Akt or a control
vector. Infection with Ad-Akt increased expression of
phosphorylated Akt, Akt and phosphorylated GSK-3b
protein (Figure 2a), consistent with previous results
demonstrating that GSK-3b acts as a substrate of Akt.
As demonstrated in Figure 2b, infection of SGC7901
cells with the Ad-Akt adenoviral vector alone had no
effect on gastric proton pump and mRNA expression.
However, infection with the Ad-Akt vector resulted in
inhibition of gastric proton pump mRNA expression
induced by HMBA compared with HMBA and infection
of the control (b-gal) adenovirus, suggesting that
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gastric cell differentiation induced by HMBA treatment.
Treatment with HMBA increased the expression and
activity of GSK-3b in the nucleus
To test whether GSK-3b was influenced by HMBA
treatment, GSK-3b activity was determined by measur-
ing the phosphorylation of recombinant Snail, a well-
characterized substrate of GSK-3b [35,36]. GSK-3b is
located in the cytosolic and nuclear compartments of
cells, but predominantly in the cytoplasm during the G1
phase. Therefore, nuclear and cytoplasmic proteins were
fractionated from control and HMBA-treated cells and
examined for GSK-3b activity. HMBA treatment
resulted in an increase in the activity of nuclear GSK-3b
(Figure 3a), and GSK-3b inhibition attenuated HMBA-
mediated G1 arrest, indicating a role for GSK-3b in
HMBA-induced cell cycle arrest. Ser9 phosphorylation
of GSK-3b decreases GSK-3b activity, whereas Tyr216
phosphorylation increases GSK-3b activity [37]. To ana-
lyze the mechanisms underlying increased GSK-3b activ-
ity caused by HMBA treatment, Ser9-phosphorylated
Figure 1 Inhibition of GSK-3b attenuates HMBA-induced cell cycle arrest and SGC7901 cell differentiation. A, SGC7901 cells were pre-
treated with or without 10 mM LiCl for 30 min followed by combination treatment with 10 mM HMBA for 24 h, followed with quantifying of
DNA content by flow cytometry. B, SGC7901 cells were treated with HMBA (10 mM) for 24 h or 48 h and were prepared for western blotting
analysis. C&E, SGC7901 cells were pre-treated with or without 10 mM LiCl or 10 μMSB-415286 for one hour followed by combination treatment
with 10 mMHMBA for 24 h. proton pump expression status was determined via western blotting analysis. D&F, total RNA was extracted from
cells and Q-RT-PCR analysis for proton pump mRNA expression was performed. (Data represent mean ± SD; * = p < 0.05 vs. control; * = p <
0.05 vs. HMBA alone.).
Wei et al. BMC Cancer 2011, 11:109
http://www.biomedcentral.com/1471-2407/11/109
Page 4 of 12and Tyr216-phosphorylated GSK-3b protein expression
was determined using western blotting. HMBA treat-
ment increased nuclear expression levels of total
GSK-3b and Tyr216-phosphorylated GSK-3b without
affecting their expression in the cytosol (Figure 3b).
Interestingly, HMBA treatment increased Ser9-phos-
phorylated GSK-3b protein expression in both the cyto-
solic and nuclear fractions. Similar results were obtained
following treatment with other HPCs, SAHA and EMBA
(Additional file 2). In addition, HPC increased the activ-
ity of GSK-3b in the nucleus as demonstrated by
in vitro kinase assays (Additional file 3). These results
suggest that HPC increases nuclear GSK-3b activity irre-
spective of phosphorylation at Ser9.
Inhibition of GSK-3b overrides HMBA-induced CDK2
inhibition
Progression through G1 is dependent on CDK2 and
CDK4 [38,39]. To determine whether GSK-3b regulation
of HMBA-mediated G1 cell cycle arrest occurs via
CDK2 or CDK4 inhibition, SGC7901 cells were pre-
treated with LiCl (Figure 4a) or SB-415286 (Figure 4b)
and then subjected to combination treatment with
HMBA for 24 h before immunoprecipitation assays
were carried out on the cell lysates using anti-CDK2 or
anti-CDK4 antibodies, respectively. In addition, CDK2
or CDK4 activity was determined using an in vitro
kinase assay. Treatment with HMBA alone inhibited
CDK2 activity (top, left panel) but increased CDK4
activity (top, right panel); inhibition of GSK-3b using
LiCl or SB-415286 significantly attenuated HMBA inhi-
bition of CDK2 activity (bottom). Treatment with
HMBA increased the expression and activity of GSK-3b
in the nucleus. Taken together, these results suggest
that GSK-3b contributes to HMBA-mediated G1 cell
cycle arrest through inhibition of CDK2.
GSK-3b regulates nuclear p27
Kip1 protein expression
To examine the mechanisms underlying HMBA
mediated G1 arrest and CDK2 inhibition further, cell
cycle-regulatory mRNA expression was analyzed using
RPA assays. Treatment with HMBA increased P27
Kip1
mRNA expression but decreased p53, p57, P15 (Figure
5A right), cyclin A and cyclin D1 mRNA expression
(Figure 5A left). However, treatment with LiCl increased
p21
Waf1 mRNA expression but did not affect the expres-
sion levels of other genes. Similar results were obtained
when cells were treated with SB-415286 (Additional
file 4). These results suggest that GSK-3b regulation of
HMBA-mediated cell cycle arrest does not involve the
transcriptional regulation of cell cycle-related genes.
To analyze the mechanisms underlying GSK-3b-asso-
ciated cell cycle arrest further, the expression of p21
Waf1
and p27
Kip1 proteins in SGC7901 cells treated with
HMBA in the presence or absence of LiCl or SB-415286
was examined. Addition of LiCl (Figure 5B right) or SB-
415286 (Figure 5B left) attenuated the induction of
p27
Kip1 but not p21
Waf1 protein expression, suggesting
Figure 2 Akt regulates gastric differentiation induced by HMBA. A, Cytosol and nuclear proteins were extracted from cells treated as
indicated and resolved on SDS-PAGE and blotted with anti-phospho-Akt, -Akt, phospho-GSK-3b, and GSK-3b, using anti-a-tubulin and Topo IIb
as control of the cytosolic and nuclear fractions respectively. B, proton pump expression was measured using western blotting followed with
abundance quantification. (Data represent mean ± SD; * = p < 0.05 vs. control; † = p < 0.05 vs. HMBA alone.). C, Total RNA (40 μg) was
fractionated, transferred to nitrocellulose membranes and probed with a labeled proton pump cDNA; blots were stripped and reprobed with
GAPDH.
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Kip1 participates in the cell cycle transitions
regulated by GSK-3b.W h e np 2 7
Kip1 accumulates in the
nucleus it binds to CDK2, inhibiting its activity, and
eventually induces cell cycle arrest. Furthermore, HMBA
(10 mM) increased p27
Kip1 p r o t e i ne x p r e s s i o ni nt h e
cytosol and nucleus from 0 to 24 h after treatment (Fig-
ure 6a). HMBA (0-5 mM) increased p27
Kip1 expression
after 24 h in cytosolic fractions and after 48 h HMBA
(5-10 mM) increased p27
Kip1 expression in nuclear frac-
tions (Figure 6b). Addition of LiCl (Figure 6c) or SB-
415286 (Figure 6d) blocked HMBA-increased p27
Kip1
nuclear expression without affecting p27
Kip1 expression
in the cytosol, suggesting specific regulation of nuclear
p27
Kip1 expression by GSK-3b. To demonstrate the role
of GSK-3b in the regulation of nuclear p27
Kip1 expres-
sion further, cells were transfected with siRNA directed
against GSK-3b (Figure 6e). RNAi-mediated suppression
of GSK-3b was confirmed by immunoblotting and atte-
nuated nuclear p27
Kip1 induction by HMBA without
affecting cytosolic p27
Kip1 induction. To confirm the
role of GSK-3b in the regulation of nuclear p27
Kip1
expression, SGC7901 cells were transfected with a vec-
tor encoding the activated form of GSK-3b (GSK-3b-
CA) or an empty control vector. Cytosol and nuclear
proteins were extracted and western blotting was per-
formed to determine p27
Kip1 expression. Transfection of
SGC7901 cells with the GSK-3bCA plasmid resulted in
increased p27
Kip1 in the nuclear fraction (Figure 6F)
without affecting p27
Kip1 levels in the cytosol. Over-
expression of the active form of GSK-3b was confirmed
using western blotting and in vitro kinase assays using
Snail protein as the substrate (Figure 6G). Taken
together, these results indicate that GSK-3b participates
in the regulation of the cell cycle through the specific
regulation of nuclear p27
Kip1 protein expression.
GSK-3b regulates p27
Kip1 binding to CDK2
HMBA increased p27
Kip1 protein expression, inhibited
CDK2 activity and increased CDK4 activity (Figure 4).
Extracts from control or HMBA-treated cells were
immunoprecipitated to investigate p27
Kip1 binding to
CDK2 and CDK4. As demonstrated in Figure 7a,
HMBA treatment increased the level of p27
Kip1 in the
complexes immunoprecipitated with anti-CDK2 but not
in complexes immunoprecipitated with anti-CDK4. Re-
probing the filters with anti-CDK2 and anti-CDK4 anti-
bodies confirmed that the immunoprecipitates from
control and HMBA-treated cells contained the same
levels of CDK2 and CDK4. Therefore, HMBA appears
to cause a selective increase in p27
Kip1 binding to
CDK2. To analyze whether inhibition of GSK-3b affects
the association of p27
Kip1 with CDK2, SGC7901 cells
were pre-treated with LiCl or SB-415286 and subjected
to combination treatment with HMBA for 24 h; whole-
cell extracts were immunoprecipitated. Treatment with
GSK-3b inhibitors, LiCl (Figure 7b) or SB-415286 (Fig-
ure 7c) blocked p27
Kip1 binding to CDK2. These results
s u g g e s tt h a tG S K - 3 b is essential for HMBA-induced
increased p27
Kip1 binding to CDK2. To confirm the role
of GSK-3b in the regulation of p27
Kip1 association with
CDK2, SGC7901 cells were transfected with a vector
encoding the activated form of GSK-3b or Ad-b-gal.
Whole-cell protein was extracted and immunoprecipi-
tated. As presented in Figure 7d, transfection of
SGC7901 cells with the GSK-3b-CA vector resulted in
an increased level of p27
Kip1 in the complexes immuno-
precipitated with anti-CDK2 compared with transfection
of the control plasmid. This suggests that GSK-3b is not
only necessary for HMBA-mediated p27
Kip1 binding to
CDK2, but also sufficient to increase the association of
p27
Kip1 with CDK2 in SGC7901 cells.
Discussion
The PI3-kinase/Akt/GSK-3b signaling pathway has been
implicated in the regulation of cell growth, apoptosis
Figure 3 Treatment with HMBA increased the expression and
activity of GSK-3b in the nucleus. A, SGC7901 cells were treated
with (+) or without (-) 10 mMHMBA for 24 h, and harvested at the
end of the treatment. Cytosol and nuclear fractions were prepared
and GSK-3b activity was assayed by in vitro kinase assay using Snail
protein as substrate. Phosphorylated Snail protein signals were
densitometrically quantitated and expressed as fold-change with
respect to untreated control groups. B, SGC7901 cells were treated
with 10 mM HMBA for various times. Cytosolic and nuclear protein
fractions were extracted and western blotting was performed using
antibodies to GSK-3b, phospho-GSK-3b (Ser9), phospho-GSK-3a/b
(Tyr278/Tyr216), a-tubulin or Topo IIb.
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Page 6 of 12Figure 4 Inhibition of GSK-3b overrides HMBA-induced CDK2 inhibition. SGC7901 cells were pre-treated with (+) or without (-) 10 mM LiCl
(A) or 10 μM SB-415286 (B) for 30 min followed by combination treatment with 10 mM HMBA for 24 h. Protein extracts were
immunoprecipitated with anti-CDK2 or anti-CDK4 antibodies. Resultant immune complexes were analyzed for CDK2 activity using histone H1 as
substrate (upper panel) or for CDK4 activity using Rb as substrate (lower panel). Phosphorylated histone H1 or Rb protein signals were
quantitated densitometrically and expressed as fold-change with respect to untreated control groups.
Figure 5 mRNA expression of genes with regard to cell cycle. A, RNase protection assays were performed using RNA from SGC7901 cells
treated with either 10 mM HMBA, 20 mM LiCl, or a combination of HMBA and LiCl for 24 h, hybridized with multi-probes for cell cycle
dependent kinase inhibitors (A; hCC-2) or cyclins (B; hCYC-1). B, SGC7901 cells were pre-treated with (+) or without (-) 10 mM LiCl (right) or 10
μM SB-415286 (left) for 30 min followed by combination treatment with 10 mM HMBA for 24 h. Whole cell protein extracts were resolved on
SDS-PAGE, transferred to PVDF membranes, and immunoblotted with antibodies to p27
Kip1, p21
Waf1, CDK2, or b-actin.
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sent study, inhibition of GSK-3b using complementary
approaches (i.e. chemical inhibition and constitutively
active Akt over-expression) attenuated proton pump
expression, a measure of gastric-like differentiation, in
the gastric tumor-derived SGC7901 cell line.
Cell proliferation and differentiation are traditionally
perceived as reciprocal processes, with cell-cycle with-
drawal being required for terminal differentiation [40],
and P27
Kip1 playing an important role [41,42]. Genetic
deletion of p27 but not p21 has been shown to affect
gastric cell differentiation, whereas forced p27
Kip1
expression leads to differentiation, suggesting that
p27
Kip1 is more important than p21
Waf1 in the regula-
tion of gastric cell differentiation. In agreement with
these findings, inhibition of GSK-3b attenuated HMBA-
mediated gastric cell differentiation and inhibition of
GSK-3b blocked HMBA-mediated nuclear p27
Kip1
expression, while over-expression of the active form of
GSK-3b increased nuclear p27
Kip1 expression, suggesting
an important role in the regulation of gastric cell differ-
entiation through the regulation of nuclear p27
Kip1
expression. Previous studies have demonstrated that
inhibition of the PI3-kinase pathway or over-expression
of PTEN increases p27
Kip1 levels and enhances cell dif-
ferentiation [43,44]. Consistent with the results pre-
sented herein, inactivation of GSK-3b using LiCl results
in down-regulation of p27
Kip1 and cell cycle progression
in primary human T cells [45].
HPC decreases the phosphorylation of Akt [8,47], and
therefore decreases the phosphorylation of GSK-3b
at Ser9. Ser9 phosphorylation of GSK-3b decreases
Figure 6 Nuclear p27
Kip1 expression modulated by GSK-3b. A& B, SGC7901 cells were treated with HMBA (10 mM) over a time course (A) or
with various concentrations for 24 h. Cytosolic and nuclear protein fractions were extracted and western blotting was performed with antibodies
to p27
Kip1, a-tubulin or Topo IIb. C& D, SGC7901 cells were pre-treated with (+) or without (-) 20 mM LiCl (C) or 10 μM SB-415286 (D) for 30 min
followed by combination treatment with 10 mM HMBA for 24 h. Cytosol and nuclear proteins were extracted for analysis of p27
Kip1 protein
expression. E, SGC7901 cells were transfected with siRNA directed to GSK-3b or control siRNA. Twenty-four hours after transfection, cells were
treated with HMBA for an additional 24 h. Cytosol and nuclear proteins were extracted for analysis of p27
Kip1 protein expression. Knockdown of
GSK-3b expression was confirmed by western blotting using anti-GSK-3b antibody. F, SGC7901 cells were infected with Ad-HA-GSK-3bS9A or Ad-
b-gal at an MOI of 10 pfu/cell. After 48 h incubation, cytosol and nuclear protein were extracted and western blotting performed using anti-
p27
Kip1, anti-HA, and anti-GSK-3 antibodies, respectively using anti-a-tubulin or Topo IIb as loading control. GSK-3b activities were assayed by in
vitro kinase assay using Snail protein as substrate (bottom panel). p27
Kip1 signals were quantitated densitometrically and expressed as fold-
change with respect to a-tubulin or TopIIb.
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increases GSK-3b activity [37]. In the present study,
HPC decreased Akt phosphorylation significantly in the
cytosol but only a minor effect was noted in the
nucleus. These results suggest that the induction of
GSK-3b activity in the nucleus may not be due to
dephosphorylated Akt, which should result in the
dephosphorylation of GSK-3b at Ser9, as treating
SGC7901 cells with HPC increased GSK-3b phosphory-
lation at Ser9. HPC increased total GSK-3b protein
expression and GSK-3b phosphorylation at Tyr216, but
the mechanisms underlying GSK-3b activation in the
nucleus by HPC, which could involve novel pathways or
additional regulatory elements for GSK-3b, remain to be
elucidated.
Nuclear GSK-3b expression is related to cell cycle pro-
gression [48]. GSK-3b is predominantly cytoplasmic dur-
ing the G1 phase [48], but a significant fraction enters
the nucleus during the S phase [49,50]. HMBA increased
expression and activity of nuclear GSK-3b and induced
G1 cell cycle arrest, which was attenuated by GSK-3b
inhibition. These results demonstrate a role for GSK-3b
in the modulation of G1 cell cycle progression. In addi-
tion to attenuation of G1 arrest, treatment with GSK-3b
inhibitors increased the cell population in the G2/M
phase. GSK-3b may regulate G2/M through the regula-
tion of Chk1 phosphorylation, an important regulator of
the G2/M checkpoint [51,52], as SB-415286 and LiCl
enhance Chk1 phosphorylation and G2/M arrest by eto-
poside. Fluxes in levels of GSK-3b in the nucleus at criti-
cal periods could be related to the well-documented
capacity of nuclear GSK-3b to activate NF-B [53,54].
Inhibition of NF-B increases the percentage of cancer
cells in the G2/M phase [55]. Nuclear GSK-3b phosphor-
ylates cyclin D1, resulting in the export of cyclin D1 from
the nucleus [56,57]. Cyclin D1 plays distinct roles in cell
Figure 7 GSK-3b regulation of p27
Kip1 association with CDK2. A, SGC7901 cells were treated with (+) or without (-) 10 mM HMBA for 24 h.
Protein extracts were immunoprecipitated with anti-CDK2 or anti-CDK4 antibodies. Normal rabbit IgG was used as the control. The CDK2-or
CDK4-associated p27
Kip1 in the resultant immune complexes was analyzed by western blotting using anti-p27
Kip1 antibody with anti-CDK2 or
-CDK4 antibody as loading controls. B&C, SGC7901 cells were pre-treated with (+) or without (-) 10 mM LiCl (B) or 10 μM SB-415286 (C) for 30
min followed by combination treatment with 10 mM HMBA for 24 h. Protein extracts were immunoprecipitated with an anti-CDK2 antibody. The
CDK2 associated p27
Kip1 in the resultant immune complexes was analyzed similar to A. D, SGC7901 cells were infected with Ad-HA-GSK-3bCA or
vector control (Ad-b-gal) at an MOI of 10 pfu/cell. After 48 h incubation, whole cell protein was extracted and immunoprecipitated with anti-
CDK2 antibody (upper panel). p27
Kip1 was analyzed by western blotting similar to A. Overexpression of HA-tagged GSK-3CA was confirmed by
western blotting using anti-GSK-3b antibody (lower panel). GSK-3b activity was assayed by an in vitro kinase assay using Snail protein as
substrate (bottom panel).
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Page 9 of 12cycle progression through the G1 phase [58]. Collectively,
these results reveal an important role for GSK-3b in the
regulation of p27
Kip1 nuclear localization and CDK2 inhi-
bitory functions on G1/S progression.
The GSK-3b-dependent ubiquitination pathway could
serve as a post-transcriptional mechanism regulating the
stability of p27
Kip1 and its binding to CDK2 in the nucleus.
GSK-3b phosphorylates p27
Kip1 at S160 and S161, result-
ing in increased p27
Kip1 stability [59]. Therefore, HMBA
treatment could result in the phosphorylation of p27
Kip1 at
S160 and S161 in the nucleus through GSK-3b activation,
leading to nuclear p27
Kip1 accumulation and increased
p27
Kip1 binding to CKD2. In conclusion, the present study
supports a contributory role of the PI3-kinase/Akt/GSK-
3b pathway in the differentiation process of gastric cells.
Importantly, the data demonstrated that nuclear GSK-3b
increased nuclear p27
Kip1 accumulation and p27
Kip1
binding to CDK2. Inhibition of CDK2 contributed to
HMBA-mediated G1 cell cycle arrest and subsequently to
HMBA-mediated gastric cell differentiation.
Conclusions
The present study identified a novel mechanism
whereby GSK-3b affects nuclear p27
Kip1 proteolysis, and
showed that it participates in the regulation of cell cycle
progression and cell differentiation in gastric cells
induced by HMBA treatment.
Additional material
Additional file 1: Inhibition of GSK-3b by SB-415286 attenuates
HMBA-induced cell cycle arrest in SGC7901 cell. SGC7901 cells were
pre-treated with or without 10 μM SB-415286 for 30 min and subjected
to combination treatment with 10 mM HMBA for 24 h before
quantification of DNA content were carried out using flow cytometry.
Additional file 2: Treatment with EMBA and SAHA activates GSK-3b
in the nucleus. SGC7901 cells were treated with 10 mM EMBA (A) and
10 μM SAHA (B) for various times. Cytosolic and nuclear protein fractions
were extracted and western blotting was performed using antibodies to
GSK-3b, phospho-GSK-3b (Ser9), phospho-GSK-3a/b (Tyr278/Tyr216), a-
tubulin or Topo IIb.
Additional file 3: EMBA or SAHA treatment activates GSK-3b in the
nucleus. SGC7901 cells were treated with (+) or without (-) 10 mM
EMBA (A) and 10 μM SAHA (B) for 24 h, and harvested at the end of the
treatment. Cytosolic and nuclear fractions were prepared and GSK-3b
activity was assayed by in vitro kinase assay using Snail protein as a
substrate of GSK-3b.
Additional file 4: Determination of cell cycle mRNA expression in
SGC7901 cells treated with EMBA or SAHA. RNase protection assays
were performed using RNA from SGC7901 cells treated with 10 mM
EMBA(A) or 10 μM SAHA(B), 20 mM LiCl, and combination of EMBA(A) or
10 μM SAHA(B) and LiCl for 24 h, hybridized with multi-probes for cell
cycle dependent kinase inhibitors (A; hCC-2) or cyclins (B; hCYC-1).
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